Latest Daptomycin Stories

SEOUL, South Korea, Jan. 7, 2013 /PRNewswire/ -- CrystalGenomics, Inc., a clinical stage biopharmaceutical company headquartered in Korea, has just announced that it has received the draft of the Clinical Study Report (CSR) from the recently completed Phase 2a study of CG400549, a first-in-class antibiotic candidate for Methicillin-resistant Staphylococcus aureus (MRSA). This study was the first human efficacy study for CG400549 and was an open-label, exploratory study to...

Infectious diseases specialists from Austin Health are working closely with Microbiologists from the University of Melbourne to understand how Staph is becoming resistant to all antibiotic therapies. The treatment of serious infections caused by Staphylococcus aureus (Golden Staph) is complicated by the development of antibiotic resistance. Seriously ill patients, vulnerable to infections can be at additional risk if antimicrobial agents become less effective in fighting infections....

An analysis of the genome of a superbug has yielded crucial, novel information that could aid efforts to counteract the bacterium’s resistance to an antibiotic of last resort. The results of the research led by scientists from The University of Texas Health Science Center at Houston (UTHealth) are published in the Sept. 8 issue of the New England Journal of Medicine. Superbugs are bacteria that are resistant to multiple antibiotics and represent one of the most challenging health...

Mass. Eye and Ear, Harvard Medical School investigators share finding in July 2011 issue of Antimicrobial Agents and ChemotherapyHospitals struggle to prevent the infections that complicate treatment for cancer, joint replacement, heart surgery and other conditions. Hospital-acquired infections are often resistant to multiple antibiotics, leading to approximately 100,000 deaths and more than $30 billion in additional health care costs yearly. New drugs are being developed to combat these...

DALLAS, June 27, 2011 /PRNewswire/ -- ReportsnReports announces it will carry 'Daptomycin - Comprehensive patent search'Report in its store Browse the complete 'Daptomycin - Comprehensive patent search [http://www.reportsnreports.com/reports/90113-daptomycin-comprehensive-patent-search.html ] 'Report now! Search 75000+ Market Research Reports [http://www.reportsnreports.com ] Browse All Pharmaceutical Market Research Reports...

LEXINGTON, Mass., June 16, 2011 /PRNewswire-USNewswire/ -- Cubist Pharmaceuticals, Inc. today praised Rep. Phil Gingrey, R-Ga., and co-sponsors for introducing the Generating Antibiotic Incentives Now (GAIN) Bill of 2011. This critical piece of legislation was crafted to help restore a robust antibiotic development pipeline to address the growing public health threat due to emerging multi-drug-resistant (MDR) bacteria. The bi-partisan legislation calls for the enactment of specific...

SAN DIEGO, April 6, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) and Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the signing of an exclusive two-year co-promotion agreement to market DIFICID(TM) (fidaxomicin), in the United States. DIFICID is a novel antibiotic currently being reviewed for market approval by the FDA for the treatment of Clostridium difficile infection (CDI), which is also known as Clostridium difficile-associated diarrhea (CDAD). On...

RNA recycling system gone awry brings MRSA to a haltScientists have discovered a new way to attack dangerous pathogens, marking a hopeful next step in the ever-escalating battle between man and microbe.In a paper published online Feb. 10 in the journal PLoS Pathogens, scientists demonstrate that by stopping bacteria's ability to degrade RNA "“ a "housekeeping" process crucial to their ability to thrive "“ scientists were able to stop methicillin-resistant Staphylococcus aureus...

As the first step in PolyMedix's US clinical development activities with PMX-30063, it has initiated a Phase 1 clinical trial. (Vocus/PRWEB) January 12, 2011 Last November, PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, received regulatory clearance from the FDA to investigate its new antibiotic candidate, PMX-30063. PMX-30063 was inspired by a key discovery: It is possible...

MALVERN, Pa., Oct. 6 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that methicillin-resistant Staphylococcus aureus (MRSA) is the most concerning pathogen to surveyed U.S. physicians with regard to their treatment of skin and skin structure infections. A drug's activity against MRSA is among the top factors that influences U.S. physician drug selection for treating skin and skin...